Clinical trials: IV Injection
Herpes Simplex, HIV Infections
An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies
To evaluate the safety and efficacy of intermittent intravenous (IV) foscarnet in the treatment of acyclovir-resistant herpes simplex virus (HSV) infections in AIDS patients and other immunocompromised patients.
- Trial name
- NCT00002272
- Testing
- Foscarnet sodium
- Where
- United States
- Sponsor
- Astra USA
Age-Related Macular Degeneration, Retinal Vein Occlusion
Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
This study was conducted because the FDA requested clinical information on potential effects of intravitreal injections of Macugen (pegaptanib sodium injection) on the corneal endothelium from a 1-year (minimum) post-approval…
- Conditions
- Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT01573572
- Testing
- pegaptanib sodium injection
- Where
- 4 sites in United States
- Volunteers
- 131 people
- Sponsor
- Bausch & Lomb Incorporated
Osteoarthritis
A Phase I, Prospective, Randomized, Open-label, Active-Controlled Clinical Trial for Safety Evaluation of Intra-articular Injection of RegenoGel-SP for the Treatment of Moderate to Severe Osteoarthritis
This is a Phase I, prospective, active-controlled, randomized, open-label, clinical trial designed to assess the safety and tolerability of single intra-articular injection of RegenoGel-SP for the treatment of OA.
- Trial name
- NCT02188771
- Testing
- intra-articular administration of RegenoGel-SP or hyaluronic acid (HA)
- Where
- Israel
- Volunteers
- 11 people
- Sponsor
- ProCore Ltd.
Dilated Cardiomyopathy
Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy
The purpose of this study is to determine the safety and clinical effectiveness of umbilical cord mesenchymal cells transplanted by intravenous infusion in patients with heart failure.
- Trial name
- RIMECARD (NCT01739777)
- Testing
- ucMSC, Controls
- Where
- Chile
- Volunteers
- 30 people
- Sponsor
- Universidad de los Andes, Chile
HIV-1-infection
Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection
This study is designed to assess the safety and pharmacokinetic profile of 800 mg Trogarzo once every two weeks administered via "IV Push" or intramuscular injection.
- Trial name
- NCT03913195
- Testing
- ibalizumab-uiyk
- Where
- 4 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- TaiMed Biologics Inc.
Multiple Sclerosis, Relapsing-Remitting
A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
In the course of therapy escalation, the multiple sclerosis (MS) subjects with high activity of disease receive mainly mitoxantrone.
- Trial name
- REMAIN (NCT01142466)
- Testing
- Interferon beta-1a (Rebif)
- Volunteers
- 30 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Prostate Cancer
Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer
RATIONALE: Diagnostic procedures, such as technetium Tc 99m demobesin-4 followed by single-photon emission computer tomography, CT scan, and MRI, may help find prostate cancer and learn the extent of disease.
- Trial name
- NCT00989105
- Testing
- immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Cancer Research UK
Colorectal Cancer
DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have metastatic…
- Trial name
- NCT00024401
- Testing
- DHA-paclitaxel
- Where
- 6 sites in United States
- Sponsor
- Theradex
Squamous Non Small Cell Lung Cancer
A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of HLX10 + chemotherapy vs chemotherapy in subjects with locally advanced or metastatic squamous NSCLC…
- Trial name
- NCT04033354
- Testing
- HLX10, carboplatin and nab paclitaxel
- Where
- 92 sites in United States, China and 5 more
- Volunteers
- 537 people
- Sponsor
- Shanghai Henlius Biotech
Hepatitis C, Opioid Use Disorder
Rural New England Health Study (Phase 2)
This study will integrate mobile hepatitis C virus (HCV) testing and treatment with expanded syringe access in order to improve uptake of HCV testing and treatment, and reduce syringe sharing behavior in rural northern New…
- Conditions
- Hepatitis C, Opioid Use Disorder, IV Drug Usage
- Trial name
- DISCERNNE (NCT05466331)
- Testing
- Mobile Tele-HCV Care, Enhanced Usual Care
- Where
- 3 sites in United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Baystate Medical Center
Acute Coronary Syndrome, Coronary Artery Disease
Comparison of Intravenous Injection of Calcium Antagonist and Beta-blockade on Endothelial Shear Stress of Coronary Artery
Both calcium channel antagonist and beta-blocker have cardioprotective effect. Endothelial shear stress is predictive factor of clinical outcomes in patients with obstructive stenosis.
- Trial name
- NCT01171911
- Testing
- Nicardipine , Esmolol
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Nanjing Medical University
Chronic Fatigue
High-dose Ascorbic Acid Intravenous Injection Decreases Mitochondrial DNA Damage in Chronic Fatigue Patients: Randomized-controlled Study
Reactive Oxygen Species (ROS) can cause oxidative damage, resulting in oxidation of lipids, proteins and DNA. In fatigue patients, there are some evidences of oxidative damage to DNA.
- Trial name
- NCT01926132
- Testing
- ascorbic acid 10g/20ml, Normal Saline 150ml
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Colorectal Cancer, Metastatic Cancer
Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer
RATIONALE: Inserting the interleukin-12 gene into a person's cancer cells may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00072098
- Testing
- adenovirus vector, interleukin-12 gene
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Max Sung
Huntington Disease
A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease.
This is a dose escalation and expansion clinical study to evaluate the safety, tolerability, PK profile and preliminary efficacy of ER2001 Injection vs. placebo in subjects with definitive diagnosis of early manifest HD.
- Trial name
- NCT07339514
- Testing
- ER2001 intravenous injection
- Where
- 3 sites in China
- Volunteers
- 27 people
- Sponsor
- ExoRNA Bioscience
Glioma
A Microdose Evaluation Study of ABY-029 in Recurrent Glioma
The primary study objective is to determine if microdoses of ABY-029 lead to detectable signals in sampled tissues with an EGFR pathology score ≥ 1 based on histological staining.
- Trial name
- ABY-029 (NCT02901925)
- Testing
- ABY-029
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Respiratory Tract Infections, Urinary Tract Infections
Study on Cefotaxime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection
In the proposed study, the investigators plan to evaluate the efficacy and safety of Cefotaxime sodium and sulbactam sodium for injection (2:1)for the treatment of respiratory and urinary tract acute bacterial infection under the…
- Trial name
- SWSB (NCT01426191)
- Testing
- xinzhijun
- Volunteers
- 2,032 people
- Sponsor
- Xiangbei Welman Pharmaceutical Co., Ltd
Intraocular Melanoma, Malignant Conjunctival Neoplasm
Vaccine Therapy in Treating Patients With Advanced Melanoma
RATIONALE: Vaccine therapy may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized clinical trial is studying how well vaccine therapy works in treating patients with advanced melanoma.
- Conditions
- Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
- Trial name
- Mel48 (NCT00705640)
- Testing
- incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Craig L Slingluff, Jr
Hemophilia A
Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A
Primary objective To assess the half-life of BIVV001, Standard Half-Life (SHL) rFVIII and Extended Half-Life (EHL) rFVIII after a single intravenous (IV) injection Secondary objectives To characterize additional pharmacokinetic…
- Trial name
- NCT05042440
- Testing
- Efanesoctocog alfa, Octocog alfa, Rurioctocog alfa pegol
- Where
- Bulgaria
- Volunteers
- 13 people
- Sponsor
- Sanofi
Bradykinin-mediated Angioedema, Hereditary Angioedema (HAE)
A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema
This is a phase IV clinical study. The investigators collect patients with a diagnosis of bradykinin induced angioedema. For a specific study period and prospectively arrange, the eligible patients who has an acute attack of…
- Trial name
- NCT07290855
- Testing
- Icatibant Injection (Icanticure®)
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- Nang Kuang Pharmaceutical Co., Ltd.
HGG, High Grade Glioma (III or IV)
A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma
The primary objective of this study is to determine the safe dose range of NRG-103 in patients and to recommend the dosage for subsequent treatment, while also evaluating the preliminary efficacy and tolerability of the product.
- Conditions
- HGG, High Grade Glioma (III or IV), High Grade Glioma
- Trial name
- NCT07710690
- Testing
- NRG-103
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Neuregen Therapeutics Co., Ltd.